期刊文献+

他克莫司治疗药物监测进展 被引量:14

在线阅读 下载PDF
导出
摘要 目的 综述他克莫司在器官移植术后临床治疗中药物浓度监测的进展。方法 查阅近年来国内外相关文献,进行分析、整理、归纳及总结。结果 他克莫司的药动学无论是个体内,还是个体间均存在着明显的个体差异;谷浓度ρ0与毒性反应有较好的相关性,而对抗排异反应的相关性的结果仍具争议;ρ0与AUC的相关关系,不同的作者给出不同的结果,相关系数,范围从0.11到0.94;谷浓度ρ0作为他克莫司血中药-时曲线下面积AUC的预测,结果各异。结论 ρ0并不是作为个体化给药的指南的最佳值,建议用两个时间的浓度(即ρ0和2—5h中的任一点)或单个时间的浓度(ρ4或ρ5)作为器官移植术后抗排异治疗个体化给药的指南为佳。
出处 《中国药学杂志》 CAS CSCD 北大核心 2007年第1期6-9,共4页 Chinese Pharmaceutical Journal
作者简介 顾健,女,副主任药师Tel:(010)68314422-5749
  • 相关文献

参考文献33

  • 1BULTYNCK G,DE-SMET P,WEIDEMA A F,et al. Effect of the immunosuppressant FKS06 on intracellular Ca^2+ release and Ca^2+ accumulation mechanisms [ J ]. J Physiol, 2000,525 ( 3 ) :681-693.
  • 2SHER L S, COSENZA C A, MICHEL J, et o2. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation : areport of the U. S. mudficenter liver study group [J]. Transplantation,1997, 64 (2) :258-263.
  • 3JOHNSTON A, HOLT D W. Therapeutic drug monitoring of immunosuppressant drugs[J]. Br J Clin Pharmacol, 1999,47:339- 350.
  • 4VENKATARAMANAN R, SWAMINATHAN A, PRASAD T, et al. Clinical pharmacokinefics of tacrolimus [ J ]. Clin Pharmacokinet, 1995,29:404-430.
  • 5AUMENTE-RUBIO M D, ARIZON-DEL-PRADO J M, LOPEZMALO M D, et al. Clinical pharmacokinetlcs of tacrolimus in heart transplantation:new strategies of monitoring[ J ]. Transplant Proc ,2003,335 : 1988-1991.
  • 6KAHAN B D, KEOWN P, LEVY G A, et o2. Therapeutic drug monitoring of immunosuppressant drug in clinical practice [ J ]. Clin Atherapeutics ,2002, 24:330-350.
  • 7陈业辉,郑克立,陈立中,戴宇平,费继光,王长希,魏鸿蔼,王良圣,胡建波.口服他克莫司血药浓度-时间曲线下面积[J].中华泌尿外科杂志,2004,25(11):750-752. 被引量:10
  • 8STAATZ C E, TETT S E. Clinical phannaeokinefics and phannacodynamics of tacrolimus in solid organ transplantation [ J ]. ClinPharmacokinet ,2004,43:623-653.
  • 9刘昭升,谢立信,史伟云.环孢霉素A缓释制剂在眼科的应用[J].国外医学(眼科学分册),2000,24(5):303-307. 被引量:11
  • 10张鑫,刘志红,郑敬民,陈朝红,唐政,陈劲松,黎磊石.细胞色素P450 3A5和多药耐药基因1基因多态性在肾移植患者他克莫司血药浓度监测中的应用[J].肾脏病与透析肾移植杂志,2004,13(4):313-317. 被引量:21

二级参考文献54

  • 1Paulussen A, Lavrijsen K, Bohets H, et al. Two linked mutations in tran scriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics,2000,10(5) :415
  • 2Lee SJ, Usmani K, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics, 2003,13: 461
  • 3Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.Proc Natl Acad Sci U S A, 1987,84:7735
  • 4Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev, 1997,27(2-3) :201
  • 5Zhang Y, Benet LZ. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet,2001,40:159
  • 6Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.Drugs, 1997,54:925
  • 7Zheng H, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms.Am J Transplant, 2003,3 (4): 477
  • 8Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyelosporine and tacrolimus. Clin Pharmacol Ther,2003,74(3) :245
  • 9Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation,2003,76(8) :1233
  • 10Zheng H, Zeevi A, Schuetz E, et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.J Clin Pharmacol, 2004,44(2): 135

共引文献46

同被引文献92

引证文献14

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部